Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Payables: 2011-2024

Historic Payables for Adma Biologics (ADMA) over the last 11 years, with Dec 2024 value amounting to $20.2 million.

  • Adma Biologics' Payables rose 49.94% to $24.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $94.6 million, marking a year-over-year increase of 50.08%. This contributed to the annual value of $20.2 million for FY2024, which is 29.11% up from last year.
  • Adma Biologics' Payables amounted to $20.2 million in FY2024, which was up 29.11% from $15.7 million recorded in FY2023.
  • In the past 5 years, Adma Biologics' Payables registered a high of $111.1 million during FY2020, and its lowest value of $12.4 million during FY2021.
  • In the last 3 years, Adma Biologics' Payables had a median value of $15.7 million in 2023 and averaged $16.4 million.
  • Per our database at Business Quant, Adma Biologics' Payables tumbled by 88.81% in 2021 and then increased by 29.11% in 2024.
  • Over the past 5 years, Adma Biologics' Payables (Yearly) stood at $111.1 million in 2020, then plummeted by 88.81% to $12.4 million in 2021, then increased by 6.43% to $13.2 million in 2022, then climbed by 18.38% to $15.7 million in 2023, then rose by 29.11% to $20.2 million in 2024.